AMR Action Fund
AMR Action Fund is an investment organization that supports antimicrobial innovation by mobilizing capital across healthcare, biotechnology, research and development, pharmaceutical, and antibiotic sectors. It supports firms developing critical pathogen therapies and engages in market reform advocacy to ensure antimicrobials are valued appropriately. The organization seeks to accelerate commercialization and aims to help bring two to four new antimicrobials to market over the next decade, while fostering a sustainable investment environment for antimicrobial innovation.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Series H
F2G
Series H in 2024
F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.